Towards curative therapy in gastric cancer: Faraway, so close!

World Journal of Gastroenterology

Volumn 21, Issue 41, 2015, Pages 11609-11620

  Cravo, Marília ^a   Fidalgo, Catarina ^a   Garrido, Rita ^a   Rodrigues, Tinia ^a   Luz, Goncalo ^a   Palmela, Carolina ^a   Santos, Marta ^a   Lopes, Fábio ^a   Maio, Rui ^a  

^a HOSPITAL BEATRIZ ÂNGELO   (Portugal)

Author keywords

Curative surgery; Gastric cancer; Multidisciplinary treatment; Therapeutic strategies

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HOST FACTOR;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CYTOTOXICITY; DRUG RESPONSE; GASTRECTOMY; GENETIC HETEROGENEITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; LAPAROSCOPIC SURGERY; LIFESTYLE MODIFICATION; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); MICROMETASTASIS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PATIENT COMPLIANCE; PERIOPERATIVE PERIOD; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; STEM CELL; STOMACH CANCER; STOMACH CARCINOGENESIS; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; TOTAL STOMACH RESECTION; TREATMENT RESPONSE; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ANIMAL; DISEASE FREE SURVIVAL; GENETICS; MINIMAL RESIDUAL DISEASE; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANIMALS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; GASTRECTOMY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM MICROMETASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PRECISION MEDICINE; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84947278821     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i41.11609     Document Type: Article

References (94)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
2. González CA, Sala N, Rokkas T. Gastric cancer: epidemiologic aspects. Helicobacter 2013; 18 Suppl 1: 34-38 [PMID: 24011243 DOI: 10.1111/hel.12082]
3. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ. Management of precancerou s conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digesti va (SPED). Endoscopy 2012; 44: 74-94 [PMID: 22198778 DOI: 10.1055/s-0031-1291491]
4. Massarrat S, Stolte M. Development of gastric cancer and its prevention. Arch Iran Med 2014; 17: 514-520 [PMID: 24979566]
5. Denova-Gutiérrez E, Hernández-Ramírez RU, López-Carrillo L. Dietary patterns and gastric cancer risk in Mexico. Nutr Cancer 2014; 66: 369-376 [PMID: 24628363 DOI: 10.1080/01635581.2014 .884237]
6. González CA, Pera G, Agudo A, Palli D, Krogh V, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Agren A, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Allen N, Bingham S, Day N, Miller A, Nagel G, Boeing H, Overvad K, Tjonneland A, Bueno-De-Mesquita HB, Boshuizen HC, Peeters P, Numans M, Clavel-Chapelon F, Helen I, Agapitos E, Lund E, Fahey M, Saracci R, Kaaks R, Riboli E. Sm oking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003; 107: 629-634 [PMID: 14520702]
7. Ladeiras-Lopes R, Pereira AK, Noguei ra A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, Lunet N. Smoking and gastric cancer: systematic review and meta-Analysis of cohort studies. Cancer Causes Control 2008; 19: 689-701 [PMID: 18293090 DOI: 10. 1007/s10552-008-9132-y]
8. Duell EJ, Travier N, Lujan-Barroso L, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Quirós JR, Sánchez-Can talejo E, Navarro C, Gurrea AB, Dorronsoro M, Khaw KT, Allen NE, Key TJ, Bueno-de-Mesquita HB, Ros MM, Numans ME, Peeters PH, Trichopoulou A, Naska A, Dilis V, Teucher B, Kaaks R, Boeing H, Schütze M, Regner S, Lindkvist B, Johansson I, Hallmans G, Overvad K, Egeberg R, Tjø nneland A, Lund E, Weiderpass E, Braaten T, Romieu I, Ferrari P, Jenab M, Stenling R, Aune D, Norat T, Riboli E, González CA. Alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr 2011; 94: 1266-1275 [PMID: 21993435 DOI: 10.3945/ajcn. 111.012351]
9. Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, Boeing H, Del Giudice G, Palli D, Saieva C, Krogh V, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Hallmans G, Sanchez MJ, Larrañaga N, Barricarte A, Chirlaque MD, Quiró s JR, Key TJ, Allen N, Lund E, Carneiro F, Linseisen J, Nagel G, Overvad K, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, OckéMO, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Fenger C, Stenling R, Ferrari P, Jenab M, Norat T, Riboli E, Gonzalez CA. Endogenous versus exogenous exposure to N-nitroso compoun d s and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006; 27: 1497-1501 [PMID: 16571648]
10. Ge S, Feng X, Shen L, We i Z, Zhu Q, Sun J. Association between Habitual Dietary Salt Intake and Risk of Gastric Cancer: A Systematic Review of Observational Studies. Gastroenterol Res Pract 2012; 2012: 808120 [PMID: 23125851 DOI: 10.1155/20 12/808120]
11. Zamora-Ros R, Agudo A, Luján-Barroso L, Romieu I, Ferrari P, Knaze V, Bueno-de-Mesquita HB, Leenders M, Travis RC, Navarro C, Sánchez-Cantalejo E, Slimani N, Scalbert A, Fedirko V, Hjartåker A, Engeset D, Skeie G, Boeing H, Förster J, Li K, Teucher B, Agnoli C, Tumino R, Mattiello A, Saieva C, Johansson I, Stenling R, Redondo ML, Wallström P, Ericson U, Khaw KT, Mulligan AA, Trichopoulou A, Dilis V, Katsoulis M, Peeters PH, Igali L, Tjønneland A, Halkjae r J, Touillaud M, Perquier F, Fagherazzi G, Amiano P, Ardanaz E, Bredsdorff L, Overvad K, Ricceri F, Riboli E, González CA. Dietary flavonoid and lignan intake and gastric adenocarcinoma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr 2012; 96: 1398-1408 [PMID: 23076618 DOI: 10.3945/ajcn.112.037358]
12. Gonzalez CA, Lujan-Barroso L, Bueno-de-Mesquita HB, Jenab M, Duell EJ, Agudo A, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Touillaud M, Teucher B, Kaaks R, Boeing H, Steffen A, Trichopoulou A, Roukos D, Karapetyan T, Palli D, Tagliabue G, Mattiello A, Tumino R, Ricceri F, Siersema PD, Numans ME, Peeters PP, Parr CL, Skeie G, Lund E, Quirós JR, Sánchez-Cantalejo E, Navarro C, Barricarte A, Dorronsoro M, Ehrnström R, Regner S, Khaw KT, Wareham N, Key TJ, Crowe FL, Blaker H, Romieu I, Riboli E. Fruit and vegetabl e intake and the risk of gastric adenocarcinoma: a reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study after a longer follow-up. Int J Cancer 2012; 131: 2910-2919 [PMID: 22473701 DOI: 10.1002/ijc.27565]
13. Serafini M,Jakszyn P,Luján-Barroso L,Agudo A,Bas Buenode-Mesquita H,van Duijnhoven FJ,Jenab M,Navarro C,Palli D,Boeing H,Wallström P,Regnér S,Numans ME,Carneiro F,Boutron-Ruault MC,Clavel-Chapelon F,Morois S,Grioni S,Panico S,Tumino R,Sacerdote C,Ramon Quiró s J,Molina-Montes E,Huerta Castaño JM,Barricarte A,Amiano P,Khaw KT,War eham N,Allen NE,Key TJ,Jeurnink SM,Peeters PH,Bamia C,Valanou E,Trichopoulou A,Kaaks R,Lukanova A,Bergmann MM,Lindkvist B,Stenling R,Johansson I,Dahm CC,Overvad K,Jensen M,,Olsen A,Tjonneland A,Lund E,Rinaldi S,Michaud D,Mouw T,Riboli E,González CA. Dietary total antioxidant capacity and gastric cancer risk in the European prospective investigation into cancer and nutrition study. Int J Cancer 2012 131 E544-E554 PMID: 22072493 DOI: 10.1002/ijc.27347]
14. Buckland G, Travier N, Huerta JM, Bueno-de-Mesquita HB, Siersema PD, Skeie G, Weiderpass E, Engeset D, Ericson U, Ohlsson B, Agudo A, Romieu I, Ferrari P, Freisling H, Colorado-Yohar S, Li K, Kaaks R, Pala V, Cross AJ, Riboli E, Trichopoulou A, Lagiou P, Bamia C, Boutron-Ruault MC, Fagherazz i G, Dartois L, May AM, Peeters PH, Panico S, Johansson M, Wallner B, Palli D, Key TJ, Khaw KT, Ardanaz E, Overvad K, Tjø nneland A, Dorronsoro M, Sánchez MJ, Quirós JR, Naccarati A, Tumino R, Boeing H, Gonzalez CA. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer 2015; 137: 598-606 [PMID: 25557932 DOI: 10.1002/ijc.29411]
15. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-Analysis. J Natl Cancer Inst 2003; 95: 1784-1791 [PMID: 14652240]
16. Algra AM, Rothwell PM. Effects of regular aspirin on longterm cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 20 12; 13: 518-527 [PMID: 22440112 DOI: 10.1016/S1470-2045(12)70112-2]
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
18. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]
19. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-3560 [PMID: 3288329]
20. Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 2003; 14: 1705-1713 [PMID: 1463 0673]
21. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem C ells 2009; 27: 1006-1020 [PMID: 19415765 DOI: 10.1002/stem.30]
22. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer orig inating from bone marrow-derived cells. Science 2004; 306: 1568-1571 [PMID: 15567866]
23. Ferrand J, Noë l D, Lehours P, Prochazkova-Carlotti M, Chambonnier L, Ménard A, Mégraud F, Varon C. Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. PLoS One 2011; 6: e19569 [PMID: 21573181 DOI: 10.1371/journal.pone.0019569]
24. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428 [PMID: 19487818 DOI: 10.1172/JCI39104]
25. Choi YJ, Kim N, Chang H, Lee HS, Park SM, Park JH, Shin CM, Kim JM, Kim JS, Lee DH, Jung HC. Helicobacter pylori-induced epithelial-mesenchymal transition, a potential role of gastric cancer initiation and an emergence of stem cells. Carcinogenesis 2015; 36: 553-563 [PMID: 25784376 DOI: 10.1093/carcin/bgv022]
26. Boige V PJ, Saint-Aubert B, Lasser P, Conroy T, BouchéO, Segol P, Bedenne L, Rougier P, Ychouet M. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial (abstract). J Clin Oncol 2007; 25: 4510
27. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; Participant s MT. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992]
28. Schuhmacher C, Gretschel S, Lordick F, Reichar dt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-5218 [PMID: 21060024 DOI: 10.1200/JCO.2009.26.6114]
29. Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 2014; 17: 213-225 [PMID: 24048758 DOI: 10.1007/s10120-013-0297-z]
30. Xiong BH, Cheng Y, Ma L, Zhang CQ. An updated meta-Analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advan ced gastric cancer. Cancer Invest 2014; 32: 272-284 [PMID: 24800782 DOI: 10.3109/07357907.2014.911877]
31. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmerma nn GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730 [PMID: 11547741]
32. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449 [PMID: 20409751 DOI: 10.1016/S1470-2045(10)70070-X]
33. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 2010; 26: 640-646 [PMID: 20827183 DOI: 10.1097/MOG.0b013e32833efd9b]
34. Persiani R,D'Ugo D,Rausei S,Sermoneta D,Barone C,Pozzo C,Ricci R,La Torre G,Picciocchi A. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy J Surg Oncol 2005 89: 227-36; discussion 237-8 PMID: 15726615]
35. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surg ical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 2006; 107: 1475-1482 [PMID: 16944539]
36. Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, Sakata Y, Saito H, Miyata Y, Hyodo I, Ando M. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 2005; 35: 714-719 [PMID: 16303791]
37. Kobayashi T, Kimura T. [Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR ) for gastric cancer]. Gan To Kagaku Ryoho 2000; 27: 1521-1526 [PMID: 11015996]
38. Nio Y, Koike M, Omori H, Hashimoto K, Itakura M, Yano S, Higami T, Maruyama R. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-A single institute study. Anticancer Res 2004; 24: 1879-1887 [PMID: 15274369]
39. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherap y in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856 [PMID: 19139439 DOI: 10.1200/JCO.2008.17.0506]
40. Leong T, Smithers M, Mi chael M, Gebski V, Boussioutas A, Miller D, Zalcberg JR, Wong R, Haustermans K. TOPGEAR: an international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric can cer (AGITG/TROG/EORTC/NCIC CTG). J Clin Oncol 2012; 30: (suppl; abstr TPS4141)
41. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM , Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012 ; 30: 268-273 [PMID: 22184384 DOI: 10.1200/JCO.2011.39.1953]
42. Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Li m HY, Kang WK. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset An alyses. J Clin Oncol 2015; 33: 3130-3136 [PMID: 25559811]
43. Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, Samantas E, Christodoulou Ch, Pentheroudakis G, Pectasides D, Dimopoulos MA, Fountzilas G. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010; 65: 1009-1021 [PMID: 20130877 DOI: 10.1007/s00280-010-1256-6]
44. Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, Choi IJ, Kim YJ, Kim DY. Phase 3 trial of postoperative chemotherap y alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys 2012; 84: e585-e592 [PMID: 22975616 DOI: 10.1016/j.ijrobp.2012.07.23 78]
45. Yu C, Yu R, Zhu W, Song Y, Li T. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol 2012; 138: 255-259 [PMID: 22105898 DOI: 10.1007/s00432-011-1085-y]
46. Kwon HC, Kim MC, Kim KH, Jang JS, Oh SY, Kim SH, Kwon KA, Lee S, Lee HS, Kim HJ. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection . Asia Pac J Clin Oncol 2010; 6: 278-285 [PMID: 21114777 DOI: 10.1111/j.1743-7563.2010.01331.x]
47. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; Investigators Ct. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomis ed controlled trial. Lancet 2012; 379: 315-321 [PMID: 22226517 DOI: 10.1016/S0140-6736(11)61873-4]
48. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Fiveyear outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-4393 [PMID: 22010012 DOI: 10.1200/JCO.2011.36.5908]
49. Ychou M, Boige V, Pignon JP, Conroy T, BouchéO, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genéve J , Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721 [PMID : 21444866 DOI: 10.1200/JCO.2010.33.0597]
50. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, Gennari L. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg 1997; 226: 613-620 [PMID: 9389395]
51. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230: 170-178 [PMID: 10450730]
52. Cho BC, Jeung HC, Choi HJ, Rha SY, Hyung WJ, Cheong JH, Noh SH, Chung HC. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. J Surg On col 2007; 95: 461-468 [PMID: 17192913]
53. Sun Z, Li DM, Wang ZN, Huang BJ, Xu Y, Li K, Xu HM. Prognostic significance of microscopic positive margins for gastric cancer patients with p otentially curative resection. Ann Surg Oncol 2009; 16: 3028-3037 [PMID: 19626373 DOI: 10.1245/s10434-009-0624-0]
54. Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol 2009; 16: 2738-2743 [PMID: 19636636 DOI: 10.1245/s10434-009-0616-0]
55. Jang YJ, Park MS, Kim JH, Park SS, Park SH, Kim SJ, Kim CS, Mok YJ. Advanced gastric cancer in the middle one-third of the stomach: Should surgeons perform total gastrectomy J Surg Oncol 2010; 101: 451-456 [PMID: 19924722 DOI: 10.1002/jso.21431]
56. Cascinu S, Giordani P, Catalano V, Agostinelli R, Catalano G. Resection-line involvement in gastric cancer patients undergoing curative resectio ns: implications for clinical management. Jpn J Clin Oncol 1999; 29: 291-293 [PMID: 10418557]
57. Macdonald JS. Gastric cancer-new therapeutic options. N Engl J Med 2006; 355: 76-77 [PMID: 16822999]
58. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. In: Wiley-Blackwell O, editor. 7th ed. USA: Wiley-Blackwell, 2009
59. B onenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H; Dutch Gastric Cancer G. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914 [PMID: 10089184]
60. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical tri al. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530 [PMID: 10188901]
61. Wanebo HJ, Kennedy BJ, Winchester DP, Fremgen A, Stewart AK. Gastric carcinoma: does lymph node dissection alter survival J Am Coll Surg 1996; 183: 616-624 [PMID: 8957465]
62. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75: 110-112 [PMID: 3349293]
63. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlle d trial. Lancet Oncol 2006; 7: 309-315 [PMID: 16574546]
64. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery fo r gastric cancer. Br J Surg 2004; 91: 283-287 [PMID: 14991627]
65. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortali ty after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995-999 [PMID: 8606613]
66. Bonenkamp J J, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-748 [PMID: 7891484]
67. Degiuli M, Sasako M, Ponti A; Italian Gastric Cancer Study G. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 v ersus D2 resection for gastric cancer. Br J Surg 2010; 97: 643-649 [PMID: 20186890 DOI: 10.1002/bjs.6936]
68. Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, Borasi A, Capussotti L, Fronda G, Morino M; Italian Gastric Cancer Study G. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014; 101: 23-31 [PMID: 24375296 DOI: 10.1002/ bjs.9345]
69. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology G. D2 lymphad enectomy alone or with para-Aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462 [PMID: 18669424 DOI: 10.1056/NEJMoa0707035]
70. Roviello F, Marrelli D, Morgagni P, de Manzo ni G, Di Leo A, Vindigni C, Saragoni L, Tomezzoli A, Kurihara H; Italian Research Group for Gastric C. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitud inal multicenter study. Ann Surg Oncol 2002; 9: 894-900 [PMID: 12417512]
71. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461 [PMID: 9790335]
72. Verlato G, Giacopuzzi S, Bencivenga M, Morgagni P, De Manzoni G. Problems faced by evidence-based medicine in evalu ating lymphadenectomy for gastric cancer. World J Gastroenterol 2014; 20: 12883-12891 [PMID: 25278685 DOI: 10.3748/wjg.v20. i36.12883]
73. de Steur WO, Dikken JL, Hartgrink HH. Lymph node dissection in resectable advanced gastric cancer. Dig Surg 2013; 30: 96-103 [PMID: 23867585 DOI: 10.1159/000350873]
74. Dikken JL, van Sandick JW, Allum WH, Johansson J, Jensen LS, Putter H, Coupland VH, Wouters MW, Lemmens VE, van de Velde CJ, van der Geest LG, Larsson HJ, Cats A, Verheij M. Differ ences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg 2013; 100: 83-94 [PMID: 23180474 DOI: 10.1002/bjs.8966]
75. Memon MA, Khan S, Yunus RM, Barr R, Memon B. Meta-Analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surg Endosc 2008; 22: 1781-1789 [PMID: 18437472 DOI: 10.1007/s00464-008-9925-9]
76. Haverkamp L, Weijs TJ, van der Sluis PC, van der Tweel I, Ruurda JP, van Hillegersberg R. Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-Analysis. Surg Endosc 2013; 27: 1509-1520 [PMID: 23263644 DOI: 10.1007/s00464-012-2661-1]
77. Waddell T,Verheij M,Allum W,Cunningham D,Cervantes A,Arnold D; European Society for Medical O European Society of Surgical O European Society o f R, Oncology. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi57-vi63 PMID: 24078663 DOI: 10.1093/annonc/mdt344]
78. Hirahara N, Tanaka T, Yano S, Yamanoi A, Minari Y, Kawabata Y, Ueda S, Hira E, Yamamoto T, Nishi T, Hyakudomi R, Inao T. Reconstruction of the gastrointestinal tract by hemi-double stapling method for the esophagus and jejunum us i ng EEA OrVil in laparoscopic total gastrectomy and proximal gastrectomy. Surg Laparosc Endosc Percutan Tech 2011; 21: e11-e15 [PMID: 21304364 DOI: 10.1097/SLE.0b013e31820747f2]
79. Kim YW, Yoon HM, Yu n YH, Nam BH, Eom BW, Baik YH, Lee SE, Lee Y, Kim YA, Park JY, Ryu KW. Long-term outcomes of laparoscopy-Assisted distal gastrectomy for early gastric cancer: result of a randomized controlled trial (COACT 0301). Surg Endosc 2013; 27: 4267-4276 [PMID: 23793805 DOI: 10.1007/s00464-013-3037-x]
80. Takiguchi S, Fujiwara Y, Yamasaki M, Miyata H, Nakajima K, Sekimoto M, Mori M, Doki Y. Laparosco py-Assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World J Surg 2013; 37: 2379-2386 [PMID: 23783252 DOI: 10.1007/s00268-013-2121-7]
81. Naka mura K, Katai H, Mizusawa J, Yoshikawa T, Ando M, Terashima M, Ito S, Takagi M, Takagane A, Ninomiya M, Fukushima N, Sasako M. A phase III study of laparoscopy-Assisted versus open distal gastrectomy with n odal dissection for clinical stage IA/IB gastric Cancer (JCOG0912). Jpn J Clin Oncol 2013; 43: 324-327 [PMID: 23275644 DOI: 10.1093/jjco/hys220]
82. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park do J, Song KY, Lee SI, Ryu SY, Lee JH; Korean Laparoscopic Gastrointestinal Surgery Study G. Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrecto my with open distal gastrectomy for gastric adenocarcinoma (KLASS 01). J Korean Surg Soc 2013; 84: 123-130 [PMID: 23396494 DOI: 10.4174/jkss.2013.84.2.123]
83. Miao RL, Wu AW. Towards perso nalized perioperative treatment for advanced gastric cancer. World J Gastroenterol 2014; 20: 11586-11594 [PMID: 25206266 DOI: 10.3748/wjg.v20.i33.11586]
84. Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol 2014; 6: 393-402 [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393]
85. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M , Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15: 2920-2926 [PMID: 19351764 DOI: 10.1158/1078-0432.CCR-08-2242]
86. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevale nce and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9: 629-635 [PMID: 18539529 DOI: 10.1016/S1470-2045(08 )70153-0]
87. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Canc er 2012; 107: 931-936 [PMID: 22871883 DOI: 10.1038/bjc.2012.350]
88. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful pro gnostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-1547 [PMID: 23530101 DOI: 10.1200/JCO.2012.45.2722]
89. Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V. NeoFLOT: Multicenter phase II study of perioperative chemother apy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer 2015; 137: 678-685 [PMID: 25530271 DOI: 10.1002/ij c.29403]
90. Webber EM, Kauffman TL, O'Connor E, Goddard KA. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer 2015; 15: 156 [PMID: 25884995 DOI: 10.1186/s12885-015-1093-4]
91. An JY, Kim H, Cheong JH, Hyung WJ, Kim H, Noh SH. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based ch emotherapy after R0 resection. Int J Cancer 2012; 131: 505-511 [PMID: 21898388 DOI: 10.1002/ijc.26399]
92. Oki E, Kakeji Y, Zhao Y, Yoshida R, Ando K, Masuda T, Ohgaki K, Morita M, Maehara Y. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol 2009; 16: 2510-2515 [PMID: 19565284 DOI: 10.1245/s10434-009-0580-8]
93. Shi J, Qu YP, Hou P. Pathogenetic mechanisms in gastric cancer. World J Gastroenterol 2014; 20: 13804-13819 [PMID: 25320518 DOI: 10.3748/wjg.v20.i38.13804]
94. Aichler M, Luber B, Lordick F, Walch A. Proteomic and metabolic prediction of response to therapy in gastric cancer. World J Gastroenterol 2014; 20: 13648-13657 [PMID: 25320503 DOI: 10.3748/wjg.v20.i38.13648]